[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aldosterone-producing-adenoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aldosterone-producing-adenoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100467540","endoscopic-ultrasound-guided-radiofrequency-ablation-in-primary-aldosteronism-100467540",false,"NCT05368090","Endoscopic Ultrasound-guided Radiofrequency Ablation in Primary Aldosteronism","Endoscopic Ultrasound-guided Radiofrequency Ablation as a Novel Treatment Option Compared With Adrenalectomy in Left-sided Primary Aldosteronism","Inclusion Criteria all groups\n\n* Signed written informed consent\n* If CT scan shows an adrenal nodule to the same adrenal as AVS lateralisation result: nodule size \\\u003C 4 cm and enhancement criteria for adrenal adenoma (native hounsfield units \\\u003C 10 or relative wash-out \\> 40% or absolute wash-out \\> 60%)\n\nPA unilateral group inclusion criteria:\n\n* Age 18 to 60 years\n* PA diagnosis confirmed according to Endocrine Society PA Guideline criteria\n* AVS lateralisation to left adrenal (lateralisation index ≥ 4,0)\n\nPA \"debulking\" group inclusion criteria:\n\n* Age 18 to 70 years\n* PA diagnosis confirmed according to Endocrine Society PA Guideline criteria\n\nMACS unilateral and debulking group inclusion criteria:\n\n* Age 18 to 80 years\n* MACS diagnosis confirmed according to ENSAT\u002FECE Guideline criteria\n* AVS lateralisation to the left adrenal, and visible left adrenal tumor on CT scan OR bilateral overproduction of cortisol on AVS, and bilateral tumors\u002Fhyperplasia on CT scan (debulking)\n\nExclusion Criteria all groups:\n\n* CT scan suspicion of adrenal malignancy\n* Patient refusal to undergo either EUS-RFA or adrenalectomy","ALL","18 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this study, the investigators will perform endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) treatment of left-sided adrenal tumours in patients with primary aldosteronism (PA) and in patients with mild autonomous cortisol secretion (MACS). Four different study groups will all receive EUS-RFA of left-sided adrenal tumours. Clinical and biochemical outcome as well as procedural safety will be evaluated. In study patients with verified lateralised aldosterone or cortisol overproduction to the left adrenal, outcome will be compared with control groups performing conventional unilateral adrenalectomy.\n\nStudy group 1: PA patients with AVS-verified left sided lateralisation and a EUS-detectable tumour in the left adrenal for EUS-RFA treatment.\n\nStudy group 2: PA patient with suspected left-sided overweight of aldosterone production and a EUS-detectable tumour but without strict lateralisation of their aldosterone overproduction, for EUS-RFA treatment as an aldosterone \"debulking\" procedure.\n\nStudy group 3: patients with MACS with AVS-verified lateralisation of cortisol overproduction to the left adrenal and EUS-detectable tumour for EUS-RFA treatment Study group 4: patients with MACS with bilateral adrenal tumours and verified bilateral overproduction of cortisol for EUS-RFA treatment as a cortisol \"debulking\" procedure.",[27,28,29],"Primary Aldosteronism","Aldosterone-Producing Adenoma","Hypercortisolism",[31,32,33,34],"radio frequency ablation","postoperative hypoaldosteronism","postoperative hypocortisolism","metabolic comorbidity","RECRUITING","2026-05-07",{"date":38,"type":39},"2026-05-08","ACTUAL",{"date":41,"type":39},"2022-06-03",{"date":43,"type":21},"2028-12-31",{"name":45,"class":46},"Haukeland University Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100595038","petal-trial-impact-of-gallium-68-pentixafor-pet-ct-on-surgical-outcomes-in-primary-aldosteronism-100595038","NCT07027254","PETAL Trial: Impact of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Primary Aldosteronism","A Randomized Controlled Trial to Evaluate the Effect of Gallium-68 Pentixafor PET-CT on Surgical Outcomes in Patients With Primary Aldosteronism (The PETAL Trial)","Inclusion Criteria:\n\n* Age ≥19 years\n* Diagnosed with PA per 2016 Endocrine Society guidelines\n* Underwent adrenal CT\n* Signed informed consent\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or may become pregnant\n* Individuals who refuse to undergo surgery\n* Individuals for whom 68Ga-Pentixafor PET\u002FCT, 11C-Metomidate PET\u002FCT, or adrenal venous sampling (AVS) is not feasible or is refused due to underlying conditions\n* Individuals who refuse or experience adverse effects from dexamethasone premedication required for 11C-Metomidate PET\u002FCT\n* Individuals with a history of abdominal open surgery or retroperitoneal surgery on the same side as the planned adrenalectomy\n* Any individual deemed unsuitable for the study at the discretion of the investigator","19 Years",{"count":57,"type":21},90,[24],"This study is a randomized controlled trial to assess the clinical utility of gallium-68 pentixafor PET\u002FCT in the management of primary aldosteronism (PA). We aim to evaluate whether the addition of 68Ga-pentixafor PET\u002FCT to standard adrenal venous sampling (AVS) improves surgical outcomes in patients with unilateral PA.",[27,61,28,62,63],"Secondary Hypertension","Idiopathic Hyperaldosteronism","Adrenalectomy",[65,66,67,68,69,70,71,63],"Primary aldosteronism","Gallium-68 pentixafor","11C-metomidate","PET\u002FCT","adrenal venous sampling","PASO","PAMO","2025-06-16",{"date":74,"type":39},"2025-06-18",{"date":76,"type":21},"2025-06-25",{"date":78,"type":21},"2027-12-01",{"name":80,"class":46},"Seoul National University Hospital",2,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":47},"100515465","multifaceted-comparison-of-ultrasound-guided-ablation-and-laparoscopic-adrenalectomy-for-aldosterone-producing-adenoma-100515465","NCT05991856","Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma","Resident Doctor, Master Degree Candidate","Inclusion Criteria:\n\n1. APA was confirmed with unilateral lesions;\n2. Benign tumor without adrenal metastasis and endovascular tumor embolus;\n3. Receive ultrasound-guided adrenal RFA treatment or laparoscopic resection, and sign the informed consent for surgery;\n4. Age ≥ 18;\n5. Age ≥ 40 years old should meet the following criteria: blood potassium ≤3.5mmol\u002FL; PAC≥20ng\u002FdL; PRC≤5μIU\u002FmL; A unilateral adrenal nodule of 10mm or more was completely normal on the opposite side.\n\nExclusion Criteria:\n\n1. Bilateral adrenal diseases;\n2. Multiple adrenal tumors;\n3. Other adrenal diseases, such as adrenal hyperplasia, Cushing's syndrome, pheochromocytoma, etc.;\n4. Imaging suggests that the tumor may be difficult to reach;\n5. Imaging showed potential malignant adrenal tumor;\n6. Pregnant and\u002For planning a pregnancy;\n7. Refusing to participate in follow-up visits.",{"count":90,"type":21},45,"OBSERVATIONAL","The purpose of this study is to retrospectively and prospectively analyze the efficacy and safety of ultrasound-guided radiofrequency ablation and laparoscopic adrenalectomy in the treatment of aldosterone-producing adenoma (APA). It is planned to retrospectively collect 30 patients with adrenal radiofrequency ablation for APA and 15 patients with age - and sex-matched laparoscopic adrenalectomy for APA in our hospital from January 2020 to June 2024, and continue to follow up for 3 years.",[94,95],"Aldosterone-producing Adenoma","Radiofrequency Ablation",[97,98,99],"aldosterone-producing adenoma","radiofrequency ablation","laparoscopic adrenalectomy","2023-08-13",{"date":102,"type":39},"2023-08-15",{"date":104,"type":39},"2020-01-01",{"date":106,"type":21},"2030-12-01",{"name":108,"class":46},"Third Affiliated Hospital, Sun Yat-Sen University"]